Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

Xue-Qing Li, Tommy B. Andersson, Marie Ahlström and Lars Weidolf
Drug Metabolism and Disposition August 2004, 32 (8) 821-827; DOI: https://doi.org/10.1124/dmd.32.8.821
Xue-Qing Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tommy B. Andersson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Ahlström
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Weidolf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 32 no. 8 821-827
DOI 
https://doi.org/10.1124/dmd.32.8.821
PubMed 
15258107

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received November 10, 2003
  • Accepted March 23, 2004
  • Published online July 16, 2004.

Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Xue-Qing Li,
  2. Tommy B. Andersson,
  3. Marie Ahlström and
  4. Lars Weidolf
  1. DMPK and Bioanalytical Chemistry, AstraZeneca R&D, Mölndal, Sweden
  1. Address correspondence to:
    Dr. Lars Weidolf, DMPK and Bioanalytical Chemistry, AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden. E-mail: lars.weidolf{at}astrazeneca.com.
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to November 2023

AbstractFullPdf
Aug 2017126245141
Sep 2017128253111
Oct 2017168281123
Nov 2017172389128
Dec 201711821091
Jan 2018148225118
Feb 201816221293
Mar 2018177274117
Apr 2018130253124
May 201895227100
Jun 20188023488
Jul 201894156183
Aug 201891153118
Sep 2018105195102
Oct 2018127232138
Nov 2018122184152
Dec 20183505259
Jan 20193512021
Feb 20193461713
Mar 20193092119
Apr 2019314147
May 20193012014
Jun 20192361819
Jul 20192532621
Aug 20192241818
Oct 20193532321
Nov 20192541425
Dec 20192532318
Jan 20202381113
Feb 20201792413
Mar 20201981919
May 20202711411
Jun 20201691512
Jul 2020167139
Aug 2020161910
Sep 2020158711
Oct 20202092028
Nov 20202391912
Dec 20202102114
Jan 2021146388
Feb 20211933010
Mar 20213362717
Apr 20212352822
May 20212562610
Jun 20212273619
Jul 20211931811
Aug 20212022617
Sep 20212111710
Oct 20212442418
Nov 20212462533
Dec 20212462912
Jan 20222431913
Feb 20222382518
Mar 20222911725
Apr 20222801915
May 20222422011
Jun 20222902527
Jul 2022220156
Aug 2022236149
Sep 20222561610
Oct 20222842916
Nov 20223392619
Dec 2022264126
Jan 2023328187
Feb 20233002214
Mar 20232822918
Apr 20232861712
May 2023254248
Jun 2023263913
Jul 20232442015
Aug 20232003212
Sep 20232871410
Oct 2023340229
Nov 20233052512

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 32 (8)
Drug Metabolism and Disposition
Vol. 32, Issue 8
1 Aug 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

Xue-Qing Li, Tommy B. Andersson, Marie Ahlström and Lars Weidolf
Drug Metabolism and Disposition August 1, 2004, 32 (8) 821-827; DOI: https://doi.org/10.1124/dmd.32.8.821

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

Xue-Qing Li, Tommy B. Andersson, Marie Ahlström and Lars Weidolf
Drug Metabolism and Disposition August 1, 2004, 32 (8) 821-827; DOI: https://doi.org/10.1124/dmd.32.8.821
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Gadoxetate-enhanced MRI and FXR in benign tumours
  • In vitro DDI assessment of peptide analogues
  • Endogenous substrates of rat organic cation transporters
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics